Validation of a prostate cancer risk calculator

Warde, Nick

doi:10.1038/nrurol.2009.241

Research Highlight
Published: January 2010

Prostate cancer

Validation of a prostate cancer risk calculator

Nick Warde

Nature Reviews Urology volume 7, page 4 (2010)Cite this article

435 Accesses
Metrics details

Subjects

Access through your institution

Buy or subscribe

Data from the Prostate Cancer Prevention Trial (PCPT) have been used to create a 'prostate cancer risk calculator', a nomogram incorporating PSA level, DRE results, previous biopsy findings, age, ethnicity and family history of prostate cancer, to provide risk estimates of biopsy-detectable disease. However, the men in the PCPT cohort had low PSA level (<3 ng/ml), normal DRE findings and were aged 55 years or older, characteristics that are not representative of men routinely referred for prostate biopsy in urology practices. Now, Eyre and colleagues have tested the generalizability of the PCPT calculator in a multicenter cohort of 645 men referred for a first prostate biopsy.

The men in the validation cohort differed significantly from the PCPT population in several characteristics, including younger age, higher PSA level, increased number of abnormal DREs, greater ethnic diversity, and more-common family history of prostate cancer. In addition, a larger proportion of men had prostate cancer, of a higher grade, in the validation cohort compared with the PCPT cohort.

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

Purchase on SpringerLink
Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

ORIGINAL RESEARCH PAPERS

Eyre, S.J. et al. Validation in a multiple urology practice cohort of the Prostate Cancer Prevention Trial calculator for predicting prostate cancer detection. J. Urol. 182, 2653–2658 (2009)
Article Google Scholar

Download references

Authors